Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma

Unknown

(2016)   BRITISH JOURNAL OF HAEMATOLOGY

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future

(2016) Nicholas J. Short et al.   Clinical Lymphoma Myeloma & Leukemia

Trends in Clinical Investigation for Myelodysplastic Syndromes

(2016) Thomas Prebet et al.   Clinical Lymphoma Myeloma & Leukemia

Preparation and characterization of a new monoclonal antibody against CXCR4 using lentivirus vector

(2016) Xinyi Li et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4

(2016) Katherine Griffiths et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Requirement of CXCL12-CXCR7 signaling for CD20− CD138− double-negative population in lymphoplasmacytic lymphoma

(2016) Naoki Wada et al.   LABORATORY INVESTIGATION

A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells

(2016) M. Broussas et al.   MOLECULAR CANCER THERAPEUTICS

Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas

(2016) Roberto Würth et al.   MOLECULAR NEUROBIOLOGY

Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies

(2016) Sheng-Bin Peng et al.   PLoS One

Pancreatic cancer stem cell markers and exosomes - the incentive push

(2016) Sarah Heiler et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Immune Complexes in Juvenile Idiopathic Arthritis

(2016) Terry L. Moore   Frontiers in Immunology

Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy

(2015) B.-S. Cho et al.   BLOOD

T-ALL: Home Is where the CXCL12 Is

(2015) Charles E. de Bock et al.   CANCER CELL

CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance

(2015) Lauren A. Pitt et al.   CANCER CELL

Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities

(2015) Koen Schepers et al.   Cell Stem Cell

CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction

(2015) Wan-Tseng Hsu et al.   CELL TRANSPLANTATION

Survival regulation of leukemia stem cells

(2015) Yiguo Hu et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy

(2015) Z. Chen et al.   CLINICAL CANCER RESEARCH

BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia

(2015) S-S Chen et al.   LEUKEMIA

Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway

(2015) Manoj K. Kashyap et al.   Oncotarget

Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells

(2015) Mohammed I. Khan et al.   Stem Cell Research & Therapy

Role of Microenvironment in Resistance to Therapy in AML

(2015) Yoko Tabe et al.   Current Hematologic Malignancy Reports

CXCL12/SDF-1 and CXCR4

(2015) Takashi Nagasawa   Frontiers in Immunology

Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome

(2015) Astrid Olsnes Kittang et al.   OncoImmunology

Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition

(2015) Edward Allan R. Sison et al.   Oncotarget

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

(2014) M. D. Galsky et al.   CLINICAL CANCER RESEARCH

Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis

(2014) Won-Tak Choi et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

CXCR4/CXCR7 Molecular Involvement in Neuronal and Neural Progenitor Migration: Focus in CNS Repair

(2014) José Joaquín Merino et al.   JOURNAL OF CELLULAR PHYSIOLOGY

CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes

(2014) Shiho Abe-Suzuki et al.   LABORATORY INVESTIGATION

Myelodysplastic syndromes

(2014) Lionel Adès et al.   LANCET

Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

(2014) K. Beider et al.   MOLECULAR CANCER THERAPEUTICS

Glycosylation of TRPM4 and TRPM5 channels: molecular determinants and functional aspects

(2014) Ninda Syam et al.   Frontiers in Cellular Neuroscience

Minimalist Hybrid Ligand/Receptor-Based Pharmacophore Model for CXCR4 Applied to a Small-Library of Marine Natural Products Led to the Identification of Phidianidine A as a New CXCR4 Ligand Exhibiting Antagonist Activity

(2013) Rosa Maria Vitale et al.   ACS Chemical Biology

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

(2013) J. Hoellenriegel et al.   BLOOD

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

(2013) Dan A. Landau et al.   CELL

HIF-2α Protects Human Hematopoietic Stem/Progenitors and Acute Myeloid Leukemic Cells from Apoptosis Induced by Endoplasmic Reticulum Stress

(2013) Kevin Rouault-Pierre et al.   Cell Stem Cell

Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12

(2013) C. Zhong et al.   CLINICAL CANCER RESEARCH

Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140

(2013) K. Beider et al.   CLINICAL CANCER RESEARCH

The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

(2013) A. Peled et al.   CLINICAL CANCER RESEARCH

The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells

(2013) L. Rosich et al.   HAEMATOLOGICA

Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growthin Vivo

(2013) David Maussang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor

(2013) D Karpova et al.   LEUKEMIA

CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance

(2013) Adam Greenbaum et al.   NATURE

The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies

(2013) Jan A. Burger et al.   SEMINARS IN CANCER BIOLOGY

Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity

(2013) Monica Gatti et al.   TOXICOLOGY

Role of CXCR4 in the Pathogenesis of Acute Myeloid Leukemia

(2013) Amnon Peled et al.   Theranostics

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

(2012) G. L. Uy et al.   BLOOD

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies

(2012) M. R. Kuhne et al.   CLINICAL CANCER RESEARCH

Development of a Unique Small Molecule Modulator of CXCR4

(2012) Zhongxing Liang et al.   PLoS One

CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges

(2012) Filomena de Nigris et al.   Recent Patents on Anti-Cancer Drug Discovery

The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor

(2011) Renee M. Mosi et al.   BIOCHEMICAL PHARMACOLOGY

Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists

(2011) Sameer P Kawatkar et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments

(2011) B. Stamatopoulos et al.   HAEMATOLOGICA

An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease

(2011) P. Giannoni et al.   HAEMATOLOGICA

CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration

(2011) Fabien M. Décaillot et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting

(2011) Marina Y. Konopleva et al.   JOURNAL OF CLINICAL ONCOLOGY

The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in

(2011) Armin Ehninger et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature

(2011) Roberto Würth et al.   JOURNAL OF NEUROIMMUNOLOGY

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist

(2011) R Parameswaran et al.   LEUKEMIA

MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias

(2011) I Spinello et al.   Blood Cancer Journal

Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib

(2010) D. Messmer et al.   BLOOD

CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth

(2010) Katia Beider et al.   EXPERIMENTAL HEMATOLOGY

Chemokines and chemokine receptors: New actors in neuroendocrine regulations

(2010) William Rostène et al.   FRONTIERS IN NEUROENDOCRINOLOGY

The Peptidomimetic CXCR4 Antagonist TC14012 Recruits β-Arrestin to CXCR7

(2010) Stéphanie Gravel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia

(2010) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

CXCR7 Protein Is Not Expressed on Human or Mouse Leukocytes

(2010) R. D. Berahovich et al.   JOURNAL OF IMMUNOLOGY

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia

(2010) F Fei et al.   LEUKEMIA

CXCR7 Functions as a Scavenger for CXCL12 and CXCL11

(2010) Ulrike Naumann et al.   PLoS One

CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells

(2010) S. Jahnichen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional diversity of SDF-1 splicing variants

(2010) Miroslaw Janowski   Cell Adhesion & Migration

CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling

(2009) A. Levoye et al.   BLOOD

Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4‐Tropic HIV Type 1

(2009) Graeme Moyle et al.   CLINICAL INFECTIOUS DISEASES

Chemokines in hematopoiesis

(2009) Hal E Broxmeyer   CURRENT OPINION IN HEMATOLOGY

Recent patents regarding the discovery of small molecule CXCR4antagonists

(2009) Cara A Mosley et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

(2009) John F. DiPersio et al.   JOURNAL OF CLINICAL ONCOLOGY

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+cell to Imatinib and Nilotinib

(2009) Falk Dillmann et al.   LEUKEMIA & LYMPHOMA

An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells

(2009) J. Kwong et al.   MOLECULAR CANCER THERAPEUTICS

AMD3100 Is a CXCR7 Ligand with Allosteric Agonist Properties

(2009) I. Kalatskaya et al.   MOLECULAR PHARMACOLOGY

 -arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7

(2009) S. Rajagopal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma

(2008) Amanda Cashen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

(2008) B. Nervi et al.   BLOOD

Control of Chemokine-Guided Cell Migration by Ligand Sequestration

(2008) Bijan Boldajipour et al.   CELL

Overexpression of Stromal Cell-Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas

(2008) F. Barbieri et al.   CLINICAL CANCER RESEARCH

The design, structures and therapeutic potential of protein epitope mimetics

(2008) John A. Robinson et al.   DRUG DISCOVERY TODAY

A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells

(2008) Tanja Nicole Hartmann et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

(2008) J A Burger et al.   LEUKEMIA

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

(2008) L. Jin et al.   MOLECULAR CANCER THERAPEUTICS

Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells

(2008) Angela Colmone et al.   SCIENCE